Jan Lycke
Professor, adjungerad
Department of Clinical-
Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort
study
A. Manouchehrinia, H. Larsson, M. E. Karim, Jan Lycke, T. Olsson, I. Kockum
Multiple Sclerosis Journal - 2023 -
Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis
registries
T. Hrnciarova, J. Drahota, T. Spelman, J. Hillert, Jan Lycke, E. K. Havrdova, E. Recmanova, J. Adamkova, J. Mares, J. Libertinova, Z. Pavelek, P. Hradilek, R. Ampapa, I. Stetkarova, M. Peterka, A. Martinkova, P. Stourac, M. Grunermelova, M. Vachova, M. Dufek, D. Horakova
Multiple Sclerosis and Related Disorders - 2023 -
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating
therapy
E. Longinetti, S. Englund, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. M. Langer-Gould, Jan Lycke, P. Nilsson, J. Salzer, A. Svenningsson, J. Mellergard, T. Olsson, F. Piehl, T. Frisell
Journal of Neurology, Neurosurgery and Psychiatry - 2023 -
CYBA allelic variants are associated with severity and recovery in Guillain-Barré
syndrome
Andreas Törnell, Nina Lagerström, Natalia Mossberg, Roberta Kiffin, Helen H. Farman, Jan Lycke, Oluf Andersen, Markus Axelsson, Kristoffer Hellstrand, Anna Martner
Journal of the peripheral nervous system - 2023 -
Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple
sclerosis.
Lenka Novakova, Marcus Henricsson, Elias Björnson, Markus Axelsson, Jan Borén, Igal Rosenstein, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
Multiple sclerosis and related disorders - 2023 -
Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Clas Malmeström, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurology - 2023 -
The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective
survey
Sofia Sandgren, Lenka Novakova, Markus Axelsson, Firoozeh Amirbeagi, I. Kockum, T. Olsson, Clas Malmeström, Jan Lycke
Frontiers in Neurology - 2023 -
Teriflunomide Concentrations in Cerebrospinal Fluid and Plasma in Patients with Multiple Sclerosis: A Pharmacokinetic
Study
Jan Lycke, Helen H. Farman, Anna Nordin
CNS Drugs - 2023 -
High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple
sclerosis
Igal Rosenstein, Markus Axelsson, Lenka Novakova, S. Rasch, Kaj Blennow, Henrik Zetterberg, Jan Lycke
FRONTIERS IN IMMUNOLOGY - 2023 -
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis
cohort
S. Englund, M. Kierkegaard, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, Jan Lycke, P. Nilsson, J. Salzer, A. Svenningsson, J. Mellergard, T. Olsson, E. Longinetti, T. Frisell, F. Piehl
Multiple Sclerosis and Related Disorders - 2023 -
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated
disorder
Magnus Johnsson, Fredrik Asztely, S. Hejnebo, Markus Axelsson, Clas Malmeström, T. Olausson, Jan Lycke
Annals of Clinical and Translational Neurology - 2022 -
Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based
study
Igal Rosenstein, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Multiple Sclerosis Journal - 2022 -
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple
sclerosis
Helen Tedeholm, Fredrik Piehl, Jan Lycke, Jenny Link, Leszek Stawiarz, Joachim Burman, P. de Flon, Katarina Fink, Martin Gunnarsson, Johan Mellergård, P. Nilsson, Peter Sundström, Anders Svenningsson, Helena Johansson, Oluf Andersen
Multiple Sclerosis and Related Disorders - 2022 -
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of
natalizumab
Magnus Johnsson, Helen H. Farman, Kaj Blennow, Henrik Zetterberg, Clas Malmeström, Markus Axelsson, Jan Lycke
Multiple Sclerosis Journal - 2022 -
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk:
Commentary
Jan Lycke, A. Svenningsson
Multiple Sclerosis Journal - 2022 -
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled
trial
A. Svenningsson, T. Frisell, J. Burman, J. Salzer, K. Fink, S. Hallberg, J. Hambraeus, Markus Axelsson, F. Al Nimer, P. Sundstrom, M. Gunnarsson, R. Johansson, J. Mellergard, Igal Rosenstein, A. Ayad, I. Sjoblom, A. Risedal, P. de Flon, Eric Gilland, J. Lindeberg, F. Shawket, F. Piehl, Jan Lycke
Lancet Neurology - 2022 -
Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and
ENHANCE
R. Hupperts, C. Gasperini, Jan Lycke, T. Ziemssen, P. Feys, S. Xiao, C. Acosta, T. Koster, J. Hobart
Therapeutic Advances in Neurological Disorders - 2022 -
MIF in the cerebrospinal fluid is decreased during relapsing-remitting while increased in secondary progressive multiple
sclerosis
S. Hjaeresen, T. Sejbaek, Markus Axelsson, S. K. Mortensen, H. Vinslov-Jensen, G. Pihl-Jensen, Lenka Novakova, C. B. Pedersen, B. Halle, F. R. Poulsen, M. L. Zhang, E. Benedikz, J. L. Frederiksen, Jan Lycke, Z. Illes, A. Fex-Svenningsen
Journal of the Neurological Sciences - 2022 -
Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple
sclerosis
Igal Rosenstein, S. Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Frontiers in Immunology - 2022 -
COVID-19 clinical outcomes and DMT of MS patients and population-based
controls
E. Longinetti, H. Bower, K. A. McKay, S. Englund, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, Jan Lycke, P. Nilsson, J. Salzer, A. Svenningsson, J. Mellergard, T. Olsson, F. Piehl, T. Frisell
Annals of Clinical and Translational Neurology - 2022 -
Smouldering multiple sclerosis: the ‘real
MS’
G. Giovannoni, V. Popescu, J. Wuerfel, K. Hellwig, E. Iacobeus, M. B. Jensen, J. M. García-Domínguez, L. Sousa, N. De Rossi, R. Hupperts, G. Fenu, B. Bodini, H. M. Kuusisto, B. Stankoff, Jan Lycke, L. Airas, C. Granziera, A. Scalfari
Therapeutic Advances in Neurological Disorders - 2022 -
Kappa free light chain index as a diagnostic biomarker in multiple sclerosis: A real-world
investigation
Igal Rosenstein, S. Rasch, Markus Axelsson, Lenka Novakova, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Journal of Neurochemistry - 2021 -
A multicentre validation study of the diagnostic value of plasma neurofilament
light.
Nicholas J. Ashton, Shorena Janelidze, Ahmad Al Khleifat, Antoine Leuzy, Emma L van der Ende, Thomas Karikari, Andrea L Benedet, Tharick A Pascoal, Alberto Lleó, Lucilla Parnetti, Daniela Galimberti, Laura Bonanni, Andrea Pilotto, Alessandro Padovani, Jan Lycke, Lenka Novakova, Markus Axelsson, Latha Velayudhan, Gil D Rabinovici, Bruce Miller, Carmine Pariante, Naghmeh Nikkheslat, Susan M Resnick, Madhav Thambisetty, Michael Schöll, Gorka Fernández-Eulate, Francisco J Gil-Bea, Adolfo López de Munain, Ammar Al-Chalabi, Pedro Rosa-Neto, Andre Strydom, Per Svenningsson, Erik Stomrud, Alexander Santillo, Dag Aarsland, John C van Swieten, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Abdul Hye, Oskar Hansson
Nature communications - 2021 -
Persons with suspicious onset of multiple sclerosis but with undetermined diagnosis had persistent lower cognition and reduced quality of
life
Clara Constantinescu, Lenka Novakova, Clas Malmeström, Radu Constantinescu, Markus Axelsson, Jan Lycke
Multiple Sclerosis and Related Disorders - 2021 -
The levels of the serine protease HTRA1 in cerebrospinal fluid correlate with progression and disability in multiple
sclerosis
S. Hjaeresen, T. Sejbaek, Markus Axelsson, H. Vinslov-Jensen, S. K. Mortensen, G. Pihl-Jensen, Lenka Novakova, J. D. R. Christensen, C. B. Pedersen, B. Halle, F. R. Poulsen, J. L. Frederiksen, M. L. Zhang, E. Benedikz, Jan Lycke, Z. Illes, A. F. Svenningsen
Journal of Neurology - 2021 -
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: An observational
study
Christina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, Sigrun Einarsdottir, Andreas Tolf, Anne Marie Landtblom, Lenka Novakova, Markus Axelsson, Clas Malmeström, Honar Cherif, Kristina Carlson, Jan Lycke, Joachim Burman
Journal of Neurology, Neurosurgery and Psychiatry - 2021 -
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients with Relapsing-Remitting Multiple Sclerosis: Data from 2 Different National
Strategies
Tim Spelman, Melinda Magyari, Fredrik Piehl, Anders Svenningsson, Peter Vestergaard Rasmussen, Matthias Kant, Finn Sellebjerg, Hanna Joensen, Jan Hillert, Jan Lycke
JAMA Neurology - 2021 -
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS
Studies
S. F. Hunter, R. A. Aburashed, R. Alroughani, A. N. Chan, D. Dive, S. Eichau, D. Kantor, H. J. Kim, Jan Lycke, R. A. L. Macdonell, C. Pozzilli, T. Scott, B. Sharrack, H. Wiendl, L. K. Chung, N. Daizadeh, D. P. Baker, P. Vermersch, I. Care-Ms Ii Camms To Care-Ms
Neurology and Therapy - 2021 -
Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk
surveillance
S. Kågström, A. Fält, A. Berglund, F. Piehl, T. Olsson, Jan Lycke
Multiple Sclerosis and Related Disorders - 2021 -
Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple
Sclerosis
Peter Alping, Joachim Burman, Jan Lycke, Frisell Thomas, Fredrik Piehl
Neurology - 2021 -
Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in
Sweden
C. Acosta, M. Gianinazzi, T. Dort, N. Armstrong, S. Ryder, T. Lundqvist, M. Ekelund, Jan Lycke
Journal of Medical Economics - 2021 -
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort
study.
Anna He, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Tim Spelman, Guillermo Izquierdo, Sara Eichau, Maria Trojano, Alessandra Lugaresi, Raymond Hupperts, Patrizia Sola, Diana Ferraro, Jan Lycke, Francois Grand'Maison, Alexandre Prat, Marc Girard, Pierre Duquette, Catherine Larochelle, Anders Svenningsson, Thor Petersen, Pierre Grammond, Franco Granella, Vincent Van Pesch, Roberto Bergamaschi, Christopher McGuigan, Alasdair Coles, Jan Hillert, Fredrik Piehl, Helmut Butzkueven, Tomas Kalincik
The Lancet. Neurology - 2020 -
Inflammation-related plasma and CSF biomarkers for multiple
sclerosis
J. Huang, M. Khademi, L. Fugger, O. Lindhe, Lenka Novakova, Markus Axelsson, Clas Malmeström, Clara Constantinescu, Jan Lycke, F. Piehl, T. Olsson, I. Kockum
Proceedings of the National Academy of Sciences of the United States of America - 2020 -
Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for
MS
Mathias Granqvist, Joachim Burman, Martin Gunnarsson, Jan Lycke, Petra Nilsson, Tomas Olsson, Peter Sundström, Anders Svenningsson, Magnus Vrethem, Thomas Frisell, Fredrik Piehl
Multiple Sclerosis Journal - 2020 -
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable
MS
Lenka Novakova, M Axelsson, Clas Malmeström, Henrik Zetterberg, Kaj Blennow, A. Svenningsson, Jan Lycke
Multiple Sclerosis and Related Disorders - 2020 -
Ultrasensitive DNA Immune Repertoire Sequencing Using Unique Molecular
Identifiers.
Gustav Johansson, Melita Kaltak, Cristiana Rîmniceanu, Avadhesh Kumar Singh, Jan Lycke, Clas Malmeström, Michael Hühn, Outi Vaarala, Susanna Cardell, Anders Ståhlberg
Clinical chemistry - 2020 -
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ
studies
G. Comi, R. Alroughani, A. L. Boster, A. D. Bass, R. Berkovich, O. Fernandez, H. J. Kim, V. Limmroth, Jan Lycke, R. A. L. Macdonell, B. Sharrack, B. A. Singer, P. Vermersch, H. Wiendl, T. Ziemssen, A. Jacobs, N. Daizadeh, C. E. Rodriguez, A. Traboulsee
Multiple Sclerosis Journal - 2020 -
Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS
studies
B. Van Wijmeersch, B. A. Singer, A. Boster, S. Broadley, O. Fernandez, M. S. Freedman, G. Izquierdo, Jan Lycke, C. Pozzilli, B. Sharrack, B. Steingo, H. Wiendl, S. Wray, T. Ziemssen, L. Chung, D. H. Margolin, K. Thangavelu, P. Vermersch
Multiple Sclerosis Journal - 2020 -
Plasma neurofilament light levels are associated with risk of disability in multiple
sclerosis
A. Manouchehrinia, P. Stridh, M. Khademi, D. Leppert, C. Barro, Z. Michalak, P. Benkert, Jan Lycke, L. Alfredsson, L. Kappos, F. Piehl, T. Olsson, J. Kuhle, I. Kockum
Neurology - 2020 -
Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple
sclerosis
Jan Lycke, S. Lenhoff
Therapeutic Advances in Neurological Disorders - 2020 -
Blood neurofilament light levels segregate treatment effects in multiple
sclerosis
Bénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, Pascal Benkert, Zuzanna Michalak, Ludwig Kappos, David Leppert, Jon A. Tsai, Tatiana Plavina, Bernd C. Kieseier, Jan Lycke, Lars Alfredsson, Ingrid Kockum, Jens Kuhle, Tomas Olsson, Fredrik Piehl
Neurology - 2020 -
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis
Patients
Peter Alping, Johan Askling, Joachim Burman, Katharina Fink, Anna Fogdell-Hahn, Martin Gunnarsson, Jan Hillert, Annette Langer-Gould, Jan Lycke, Petra Nilsson, Jonatan Salzer, Anders Svenningsson, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Thomas Frisell
Annals of Neurology - 2020 -
Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable
Therapies
G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, Jan Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, T. Frisell
JAMA Neurology - 2020 -
Natalizumab, rituximab and fingolimod as escalation therapy in multiple
sclerosis
M. Boremalm, A. Juto, Markus Axelsson, Lenka Novakova, T. Frisell, A. Svenningsson, Jan Lycke, F. Piehl, J. Selzer
European Journal of Neurology - 2019 -
Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV
infection
Linn Hermansson, Aylin Yilmaz, M Axelsson, Kaj Blennow, D. Fuchs, Lars Hagberg, Jan Lycke, Henrik Zetterberg, Magnus Gisslén
Journal of Neuroinflammation - 2019 -
An unexpectedly high occurrence of aciclovir-induced neuropsychiatric symptoms in patients treated for herpesvirus CNS infection: a prospective observational
study.
Johan Lindström, Anders Helldén, Jan Lycke, Anna Grahn, Marie Studahl
The Journal of antimicrobial chemotherapy - 2019 -
Cerebrospinal fluid growth-associated protein 43 in multiple
sclerosis.
Åsa P Sandelius, Sofia Sandgren, Markus Axelsson, Clas Malmeström, Lenka Novakova, Vesna Kostanjevecki, Manu Vandijck, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Scientific reports - 2019 -
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and
Meta-analysis.
Claire Bridel, Wessel N van Wieringen, Henrik Zetterberg, Betty M Tijms, Charlotte E Teunissen, José C Alvarez-Cermeño, Ulf Andreasson, Markus Axelsson, David C Bäckström, Ales Bartos, Maria Bjerke, Adam Boxer, Lou Brundin, Joachim Burman, Tove Christensen, Lenká Fialová, Lars Forsgren, Jette L Frederiksen, Magnus Gisslén, Elizabeth Gray, Martin Gunnarsson, Sara Hall, Oskar Hansson, Megan Herbert, Joel Jakobsson, Jan Jessen-Krut, Shorena Janelidze, Gudmundur Johannsson, Michael Jonsson, Ludwig Kappos, Mohsen Khademi, Michael Khalil, Jens Kuhle, Mikael Landén, Ville Leinonen, Giancarlo Logroscino, Ching-Hua Lu, Jan Lycke, Nadia K Magdalinou, Andrea Malaspina, Niklas Mattsson, Lieke H Meeter, Sanjay R Mehta, Signe Modvig, Tomas Olsson, Ross W Paterson, Josué Pérez-Santiago, Fredrik Piehl, Yolande A L Pijnenburg, Okko T Pyykkö, Oskar Ragnarsson, Julio C Rojas, Jeppe Romme Christensen, Linda Sandberg, Carole S Scherling, Jonathan M Schott, Finn T Sellebjerg, Isabella L Simone, Tobias Skillbäck, Morten Stilund, Peter Sundström, Anders Svenningsson, Rosanna Tortelli, Carla Tortorella, Alessandro Trentini, Maria Troiano, Martin R Turner, John C van Swieten, Mattias Vågberg, Marcel M Verbeek, Luisa M Villar, Pieter Jelle Visser, Anders Wallin, Andreas Weiss, Carsten Wikkelsö, Edward J Wild, Kaj Blennow
JAMA neurology - 2019 -
Cerebrospinal fluid NCAM levels are modulated by disease-modifying
therapies
Markus Axelsson, N. Dubuisson, Lenka Novakova, Clas Malmeström, G. Giovannoni, Jan Lycke, S. Gnanapavan
Acta Neurologica Scandinavica - 2019 -
Sulfatide isoform pattern in cerebrospinal fluid discriminates progressive MS from relapsing-remitting
MS
Lenka Novakova, Avadhesh Kumar Singh, Markus Axelsson, Marcus Ståhlman, Martin Adiels, Clas Malmeström, Henrik Zetterberg, Jan Borén, Jan Lycke, Susanna Cardell, Maria K. Blomqvist
Journal of Neurochemistry - 2018 -
Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of
biomarkers.
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Imberg, Henrik Zetterberg, Olle Nerman, Jan Lycke
PloS one - 2018 -
Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot
study.
Markus Axelsson, Magnus Sjögren, Oluf Andersen, Kaj Blennow, Henrik Zetterberg, Jan Lycke
Acta neurologica Scandinavica - 2018 -
A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and
Iceland
Olöf Eliasdottir, Anders Hildeman, Marco Longfils, Olle Nerman, Jan Lycke
Journal of Neurology - 2018 -
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label
extension.
Raju Kapoor, Pei-Ran Ho, Nolan Campbell, Ih Chang, Aaron Deykin, Fiona Forrestal, Nisha Lucas, Bei Yu, Douglas L Arnold, Mark S Freedman, Myla D Goldman, Hans-Peter Hartung, Eva Kubala Havrdová, Douglas Jeffery, Aaron Miller, Finn Sellebjerg, Diego Cadavid, Dan Mikol, Deborah Steiner, Jan Lycke
The Lancet. Neurology - 2018 -
Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to
fingolimod
Fredrik Piehl, Ingrid Kockum, Mohsen Khademi, Kaj Blennow, Jan Lycke, Henrik Zetterberg, Tomas Olsson
Multiple Sclerosis Journal - 2018 -
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3
study
Ludwig Kappos, Amit Bar-Or, Bruce A.C. Cree, Robert J. Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L. Arnold, Sophie Arnould, Tatiana Scherz, Christian Wolf, Erik Wallström, Frank Dahlke, Anat Achiron, Lutz Achtnichts, Kadriye Agan, Gulsen Akman-Demir, Alison B. Allen, Jack P. Antel, Alfredo Rodriguez Antiguedad, Michelle Apperson, Angela M. Applebee, Guillermo Izquierdo Ayuso, Masayuki Baba, Ovidiu Bajenaru, Rodica Balasa, Belgin Petek Balci, Michael Barnett, Ann Bass, Veit U. Becker, Mihaela Bejinariu, Florian Then Bergh, Arnfin Bergmann, Evanthia Bernitsas, Achim Berthele, Virender Bhan, Felix Bischof, Randall John Bjork, Gregg Blevins, Matthias Boehringer, Thomas Boerner, Robert Bonek, James D. Bowen, Allen Bowling, Alexey N. Boyko, Cavit Boz, Vera Bracknies, Stefan Braune, Vincenzo Brescia Morra, Bruno Brochet, Waldemar Brola, Paul Kenneth Brownstone, Miroslav Brozman, Donald Brunet, Ioan Buraga, Margaret Burnett, Mathias Buttmann, Helmut Butzkueven, Jonathan Cahill, Jonathan C. Calkwood, William Camu, Mark Cascione, Giovani Castelnovo, Diego Centonze, Joao Cerqueira, Andrew Chan, Andrea Cimprichova, Stanley Cohan, Giancarlo Comi, Jill Conway, Joanna A. Cooper, John Corboy, Jorge Correale, Brian Costell, David A. Cottrell, Patricia K. Coyle, Matthew Craner, Liying Cui, Luis Cunha, Anna Czlonkowska, Ana Martins da Silva, Joao de Sa, Jérôme de Seze, Marc Debouverie, Jan Debruyne, Danny Decoo, Gilles Defer, Tobias Derfuss, Norma H. Deri, Bhupesh Dihenia, Peter Dioszeghy, Vladimir Donath, Benedicte Dubois, Martin Duddy, Pierre Duquette, Gilles Edan, Husnu Efendi, Stanton Elias, Jan Lycke
The Lancet - 2018 -
Trials of antivirals in the treatment of multiple
sclerosis
Jan Lycke
Acta Neurologica Scandinavica - 2017 -
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple
sclerosis.
Lenka Novakova, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Thomas Olsson, Jan Lycke
Multiple sclerosis (Houndmills, Basingstoke, England) - 2017 -
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological
Society
M. Vagberg, Markus Axelsson, R. Birgander, J. Burman, C. Cananau, Y. Forslin, T. Granberg, M. Gunnarsson, A. von Heijne, Lars Jönsson, V. D. Karrenbauer, E. M. Larsson, T. Lindqvist, Jan Lycke, L. Lonn, E. Mentesidou, S. Muller, P. Nilsson, F. Piehl, A. Svenningsson, M. Vrethem, J. Wikstrom
Acta Neurologica Scandinavica - 2017 -
Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple
sclerosis.
Lenka Nováková Nyrén, Markus Axelsson, Mohsen Khademi, Henrik Zetterberg, Kaj Blennow, Clas Malmeström, Fredrik Piehl, Tomas Olsson, Jan Lycke
Journal of neurochemistry - 2017 -
Monitoring disease activity in multiple sclerosis using serum neurofilament light
protein.
Lenka Novakova, Henrik Zetterberg, Peter Sundström, Markus Axelsson, Martin Gunnarsson, Clas Malmeström, Fredrik Piehl, Kaj Blennow, Jan Lycke
Neurology - 2017 -
The role of blood and CSF biomarkers in the evaluation of new treatments against multiple
sclerosis.
Jan Lycke, Henrik Zetterberg
Expert review of clinical immunology - 2017 -
High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple
Sclerosis.
Avadhesh Kumar Singh, Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke, Susanna Cardell
Frontiers in Immunology - 2017 -
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or
mitoxantrone.
Annika Öhrfelt, Markus Axelsson, Clas Malmeström, Lenka Novakova, Amanda Heslegrave, Kaj Blennow, Jan Lycke, Henrik Zetterberg
Multiple sclerosis (Houndmills, Basingstoke, England) - 2016 -
Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the
MSIS-29
C. Gasperini, R. Hupperts, Jan Lycke, C. Short, M. McNeill, J. Zhong, L. R. Mehta
Journal of the Neurological Sciences - 2016 -
Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE
trial
Raymond Hupperts, Jan Lycke, Christine Short, Claudio Gasperini, Manjit McNeill, Rossella Medori, Agata Tofil-Kaluza, Maria Hovenden, Lahar R. Mehta, Jacob Elkins
Multiple Sclerosis - 2016 -
Rituximab in paediatric onset multiple sclerosis: a case
series
Jonatan Salzer, Jan Lycke, Ronny Wickström, Hans Naver, Fredrik Piehl, Anders Svenningsson
Journal of Neurology - 2016 -
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: Randomized RECYCLINE
study
P. S. Sørensen, F. Sellebjerg, Jan Lycke, M. Färkkilä, A. Créange, C. G. Lund, M. Schluep, J. L. Frederiksen, E. Stenager, C. Pfleger, E. Garde, E. Kinnunen, K. Marhardt
European Journal of Neurology - 2016 -
Rituximab in multiple
sclerosis
J. Salzer, R. Svenningsson, P. Alping, Lenka Novakova, A. Björck, K. Fink, P. Islam-Jakobsson, Clas Malmeström, Markus Axelsson, M. Vågberg, P. Sundström, Jan Lycke, F. Piehl, A. Svenningsson
Neurology - 2016 -
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis
Patients
P. Alping, T. Frisell, Lenka Novakova, P. Islam-Jakobsson, J. Salzer, A. Bjorck, Markus Axelsson, Clas Malmeström, K. Fink, Jan Lycke, A. Svenningsson, F. Piehl
Annals of Neurology - 2016 -
Age-dependent effects on the treatment response of natalizumab in MS
patients
H. Matell, Jan Lycke, A. Svenningsson, C. Holmen, M. Khademi, J. Hillert, T. Olsson, F. Piehl
Multiple Sclerosis Journal - 2015 -
Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple
Sclerosis
Maria Kneider, Vera Lisovskaja, Jan Lycke, Clas Malmeström, Johannes Jakobsen, Olle Nerman, Oluf Andersen
Neuroepidemiology - 2015 -
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple
sclerosis.
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Ingemar Björkhem, Virginija Danylaité Karrenbauer, Jan Lycke
Journal of the Neurological Sciences - 2015 -
Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical
outcomes
Jan Lycke
Therapeutic Advances in Neurological Disorders - 2015 -
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre
study
J. Kuhle, G. Disanto, R. Dobson, R. Adiutori, L. Bianchi, J. Topping, J. P. Bestwick, U. C. Meier, M. Marta, G. Dalla Costa, T. Runia, E. Evdoshenko, N. Lazareva, E. Thouvenot, P. Iaffaldano, V. Direnzo, M. Khademi, F. Piehl, M. Comabella, M. Sombekke, J. Killestein, H. Hegen, S. Rauch, S. D'Alfonso, J. C. Alvarez-Cermeno, P. Kleinova, D. Horakova, R. Roesler, F. Lauda, S. Llufriu, T. Avsar, U. Uygunoglu, A. Altintas, S. Saip, T. Menge, C. Rajda, R. Bergamaschi, N. Moll, M. Khalil, R. Marignier, I. Dujmovic, H. Larsson, Clas Malmeström, E. Scarpini, C. Fenoglio, S. Wergeland, A. Laroni, V. Annibali, S. Romano, A. D. Martinez, A. Carra, M. Salvetti, A. Uccelli, O. Torkildsen, K. M. Myhr, D. Galimberti, K. Rejdak, Jan Lycke, J. L. Frederiksen, J. Drulovic, C. Confavreux, D. Brassat, C. Enzinger, S. Fuchs, I. Bosca, J. Pelletier, C. Picard, E. Colombo, D. Franciotta, T. Derfuss, R. L. P. Lindberg, O. Yaldizli, L. Vecsei, B. C. Kieseier, H. P. Hartung, P. Villoslada, A. Siva, A. Saiz, H. Tumani, E. Havrdova, L. M. Villar, M. Leone, N. Barizzone, F. Deisenhammer, C. Teunissen, X. Montalban, M. Tintore, T. Olsson, M. Trojano, S. Lehmann, G. Castelnovo, S. Lapin, R. Hintzen, L. Kappos, R. Furlan, V. Martinelli, G. Comi, S. V. Ramagopalan, G. Giovannoni
Multiple Sclerosis Journal - 2015 -
Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple
sclerosis
Fredrik Asztely, E. Gilland, M. P. Wattjes, Jan Lycke
Journal of the Neurological Sciences - 2015 -
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: The Swedish
experience
Joachim Burman, Ellen Iacobaeus, Anders Svenningsson, Jan Lycke, Martin Gunnarsson, Petra Nilsson, Magnus Vrethem, Sten Fredrikson, Claes Martin, Anna Sandstedt, Bertil Uggla, Stig Lenhoff, Jan-Erik Johansson, Cecilia Isaksson, Hans Hägglund, Kristina Carlson, Jan Fagius
Journal of Neurology, Neurosurgery and Psychiatry - 2014 -
Immunosuppressive therapy reduces axonal damage in progressive multiple
sclerosis.
Markus Axelsson, Clas Malmeström, Martin Gunnarsson, Henrik Zetterberg, Peter Sundström, Jan Lycke, Anders Svenningsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2014 -
High nationwide incidence of multiple sclerosis in
Sweden
Cecilia Ahlgren, Anders Odén, Jan Lycke
PLoS ONE - 2014 -
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in
MS.
Clas Malmeström, Bengt A. Andersson, Jan Lycke
Journal of neurology - 2014 -
CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive
treatment.
Clas Malmeström, Markus Axelsson, Jan Lycke, Henrik Zetterberg, Kaj Blennow, Bob Olsson
Journal of neuroimmunology - 2014 -
MS risk genes are transcriptionally regulated in CSF leukocytes at
relapse
Margareta Jernås, Clas Malmeström, Markus Axelsson, Caroline Olsson, Intawat Nookaew, Hans Wadenvik, Henrik Zetterberg, Kaj Blennow, Jan Lycke, Mats Rudemo, Bob Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
The impact of rituximab therapy in multiple sclerosis on cerebrospinal fluid cell gene
expression
Margareta Jernås, Clas Malmeström, Intawat Nookaew, Hans Wadenvik, Bob Olsson, Jan Lycke
Multiple Sclerosis Journal: 29th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis / 18th Annual Conference of Rehabilitation in MS - 2013 -
The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple
sclerosis.
Markus Axelsson, Niklas Mattsson, Clas Malmeström, Henrik Zetterberg, Jan Lycke
Journal of Neuroimmunology - 2013 -
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple
sclerosis.
Ashley H Beecham, Nikolaos A Patsopoulos, Dionysia K Xifara, Mary F Davis, Anu Kemppinen, Chris Cotsapas, Tejas S Shah, Chris Spencer, David Booth, An Goris, Annette Oturai, Janna Saarela, Bertrand Fontaine, Bernhard Hemmer, Claes Martin, Frauke Zipp, Sandra D'Alfonso, Filippo Martinelli-Boneschi, Bruce Taylor, Hanne F Harbo, Ingrid Kockum, Jan Hillert, Tomas Olsson, Maria Ban, Jorge R Oksenberg, Rogier Hintzen, Lisa F Barcellos, Cristina Agliardi, Lars Alfredsson, Mehdi Alizadeh, Carl Anderson, Robert Andrews, Helle Bach Søndergaard, Amie Baker, Gavin Band, Sergio E Baranzini, Nadia Barizzone, Jeffrey Barrett, Céline Bellenguez, Laura Bergamaschi, Luisa Bernardinelli, Achim Berthele, Viola Biberacher, Thomas M C Binder, Hannah Blackburn, Izaura L Bomfim, Paola Brambilla, Simon Broadley, Bruno Brochet, Lou Brundin, Dorothea Buck, Helmut Butzkueven, Stacy J Caillier, William Camu, Wassila Carpentier, Paola Cavalla, Elisabeth G Celius, Irène Coman, Giancarlo Comi, Lucia Corrado, Leentje Cosemans, Isabelle Cournu-Rebeix, Bruce A C Cree, Daniele Cusi, Vincent Damotte, Gilles Defer, Silvia R Delgado, Panos Deloukas, Alessia di Sapio, Alexander T Dilthey, Peter Donnelly, Bénédicte Dubois, Martin Duddy, Sarah Edkins, Irina Elovaara, Federica Esposito, Nikos Evangelou, Barnaby Fiddes, Judith Field, Andre Franke, Colin Freeman, Irene Y Frohlich, Daniela Galimberti, Christian Gieger, Pierre-Antoine Gourraud, Christiane Graetz, Andrew Graham, Verena Grummel, Clara Guaschino, Athena Hadjixenofontos, Hakon Hakonarson, Christopher Halfpenny, Gillian Hall, Per Hall, Anders Hamsten, James Harley, Timothy Harrower, Clive Hawkins, Garrett Hellenthal, Charles Hillier, Jeremy Hobart, Muni Hoshi, Sarah E Hunt, Maja Jagodic, Ilijas Jelčić, Angela Jochim, Brian Kendall, Allan Kermode, Trevor Kilpatrick, Keijo Koivisto, Ioanna Konidari, Thomas Korn, Helena Kronsbein, Cordelia Langford, Malin Larsson, Mark Lathrop, Christine Lebrun-Frenay, Jeannette Lechner-Scott, Michelle H Lee, Maurizio A Leone, Virpi Leppä, Giuseppe Liberatore, Benedicte A Lie, Christina M Lill, Magdalena Lindén, Jenny Link, Felix Luessi, Jan Lycke, Fabio Macciardi, Satu Männistö, Clara P Manrique, Roland Martin, Vittorio Martinelli, Deborah Mason, Gordon Mazibrada, Cristin McCabe, Inger-Lise Mero, Julia Mescheriakova, Loukas Moutsianas, Kjell-Morten Myhr, Guy Nagels, Richard Nicholas, Petra Nilsson, Fredrik Piehl, Matti Pirinen, Siân E Price, Hong Quach, Mauri Reunanen, Wim Robberecht, Neil P Robertson, Mariaemma Rodegher, David Rog, Marco Salvetti, Nathalie C Schnetz-Boutaud, Finn Sellebjerg, Rebecca C Selter, Catherine Schaefer, Sandip Shaunak, Ling Shen, Simon Shields, Volker Siffrin, Mark Slee, Per Soelberg Sorensen, Melissa Sorosina, Mireia Sospedra, Anne Spurkland, Amy Strange, Emilie Sundqvist, Vincent Thijs, John Thorpe, Anna Ticca, Pentti Tienari, Cornelia van Duijn, Elizabeth M Visser, Steve Vucic, Helga Westerlind, James S Wiley, Alastair Wilkins, James F Wilson, Juliane Winkelmann, John Zajicek, Eva Zindler, Jonathan L Haines, Margaret A Pericak-Vance, Adrian J Ivinson, Graeme Stewart, David Hafler, Stephen L Hauser, Alastair Compston, Gil McVean, Philip De Jager, Stephen J Sawcer, Jacob L McCauley
Nature genetics - 2013 -
Clinical case reviews in multiple sclerosis spasticity: experiences from around
Europe.
Jürgen Koehler, Maria P Amato, Celia Oreja-Guevara, Jan Lycke
Expert review of neurotherapeutics - 2013 -
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple
sclerosis
J Kuhle, Clas Malmeström, Markus Axelsson, K Plattner, O Yaldizli, T Derfuss, G Giovannoni, L Kappos, Jan Lycke
Acta neurologica Scandinavica - 2013 -
Serum levels of LIGHT in
MS
Clas Malmeström, Alan Gillett, Margareta Jernås, Mohsen Khademi, Markus Axelsson, Ingrid Kockum, Niklas Mattsson, Henrik Zetterberg, Kaj Blennow, Lars Alfredsson, Hans Wadenvik, Jan Lycke, Tomas Olsson, Bob Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating
drugs.
Helen Tedeholm, Jan Lycke, Bengt Skoog, Vera Lisovskaja, J Hillert, C Dahle, J Fagius, S Fredrikson, A-M Landtblom, Clas Malmeström, C Martin, F Piehl, Björn Runmarker, L Stawiarz, M Vrethem, Olle Nerman, Oluf Andersen
Multiple Sclerosis Journal - 2013 -
Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple
sclerosis.
Kristin Augutis, Markus Axelsson, Erik Portelius, Gunnar Brinkmalm, Ulf Andreasson, Mikael K Gustavsson, Clas Malmeström, Jan Lycke, Kaj Blennow, Henrik Zetterberg, Niklas Mattsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2013 -
MicroRNA regulate immune pathways in T-cells in multiple sclerosis
(MS)
Margareta Jernås, Clas Malmeström, Markus Axelsson, Intawat Nookaew, Hans Wadenvik, Jan Lycke, Bob Olsson
BMC Immunology - 2013 -
Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated
syndrome
Cecilia Ahlgren, Anders Odén, Tomas Bergström, Jan Lycke
Journal of Neuroimmunology - 2012 -
A nationwide survey of the prevalence of multiple sclerosis in immigrant populations of
Sweden
Cecilia Ahlgren, Anders Odén, Jan Lycke
Multiple Sclerosis - 2012 -
Glial fibrillary acidic protein: a potential biomarker for progression in multiple
sclerosis.
M Axelsson, Clas Malmeström, Staffan Nilsson, Sara Haghighi, Lars Rosengren, Jan Lycke
Journal of neurology - 2011 -
The effect of live, attenuated measles vaccine and measles infection on measles antibody levels in serum and CSF of patients with multiple sclerosis or clinically isolated
syndrome.
Cecilia Ahlgren, Anders Odén, Sara Haghighi, Oluf Andersen, Tomas Bergström, Jan Lycke
Journal of neuroimmunology - 2011 -
reply to Letter to the Editor "The neurofilament light chain is not stable in
vitro"
M Gunnarsson, Clas Malmeström, Lars Rosengren, Jan Lycke, A Svenningsson
Annals of Neurol - 2011 -
Allmän neurologi och multipel
skleros
Jan Lycke, Mats Elm
Neurologi. Läkemedelsboken 2011–2012 - 2011 -
High nationwide prevalence of multiple sclerosis in
Sweden.
Cecilia Ahlgren, Anders Odén, Jan Lycke
Multiple sclerosis (Houndmills, Basingstoke, England) - 2011 -
Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4
trial.
Per Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, Astrid Edland, Xingchen Wu, Jette Lautrup Frederiksen, Annette Oturai, Clas Malmeström, Egon Stenager, Finn Sellebjerg, Helle Bach Sondergaard, investigators study for the SIMCOMBIN
Lancet neurology - 2011 -
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple
sclerosis.
Carolina Holmén, Fredrik Piehl, Jan Hillert, Anna Fogdell-Hahn, Malin Lundkvist, Elin Karlberg, Petra Nilsson, Charlotte Dahle, Nils Feltelius, Anders Svenningsson, Jan Lycke, Tomas Olsson
Multiple sclerosis (Houndmills, Basingstoke, England) - 2011 -
Axonal damage in relapsing multiple sclerosis is markedly reduced by
natalizumab.
Martin Gunnarsson, Clas Malmeström, Markus Axelsson, Peter Sundström, Charlotte Dahle, Magnus Vrethem, Tomas Olsson, Fredrik Piehl, Niklas Norgren, Lars Rosengren, Anders Svenningsson, Jan Lycke
Annals of neurology - 2011 -
Leukocyte myeloperoxidase and pathogenesis of the post-polio
syndrome
Charlotta Movitz, Tomas Bergström, Kristian Borg, Kristoffer Hellstrand, Erik Lycke, Jan Lycke
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES - 2010 -
Successful epilepsy surgery in a patient with
neurosarcoidosis
Kristina Malmgren, Jan Lycke, Elisabeth Engman, Anders Hedström, Lars Jönsson, Bertil Rydenhag, Claes Nordborg
Epilepsia - 2010 -
High risk of MS in Iranian immigrants in Gothenburg,
Sweden.
Cecilia Ahlgren, Jan Lycke, Anders Odén, Oluf Andersen
Multiple sclerosis journal - 2010 -
[Neuromyelitis optica--important differential diagnosis to MS. Early treatment initiation crucial for the
prognosis].
Jan Lycke, Clas Malmeström
Läkartidningen - 2010 -
Allmän neurologi och multipel
skleros
Jan Lycke, Mats Elm
Neurologi. Läkemedelsboken 2009-2010 - 2009 -
Reduced cerebrospinal fluid BACE1 activity in multiple
sclerosis.
Niklas Mattsson, M Axelsson, Sara Haghighi, Clas Malmeström, G Wu, Rolf Anckarsäter, S Sankaranarayanan, Ulf Andreasson, S Fredrikson, A Gundersen, L Johnsen, T Fladby, Andrej Tarkowski, E Trysberg, Anders Wallin, Henrik Anckarsäter, Jan Lycke, Oluf Andersen, A J Simon, Kaj Blennow, Henrik Zetterberg
Multiple sclerosis (Houndmills, Basingstoke, England) - 2009 -
Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in
CSF.
Clas Malmeström, Jan Lycke, Sara Haghighi, Oluf Andersen, Lena M S Carlsson, Hans Wadenvik, Bob Olsson
Journal of neuroimmunology - 2008 -
IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic
roles
Clas Malmeström, Bengt A. Andersson, Sara Haghighi, Jan Lycke
Journal of Neuroimmunology - 2006 -
The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir
treatment
Anders Helldén, Jan Lycke, Tatiana Vander, Jan-Olof Svensson, Ingegerd Odar-Cederlöf, Lars Ståhle
Journal of Antimicrobial Chemotherapy - 2006 -
Asymptomatic visual loss in multiple
sclerosis.
Jan Lycke, Per Olof Tollesson, Lars Frisén
Journal of neurology - 2001 -
Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind
study.
Jan Lycke, Bo Svennerholm, Elisabeth Hjelmquist, Lars Frisén, Gaby Badr, Mats Andersson, A Vahlne, Oluf Andersen
Journal of neurology - 1996